Prices of Pfizer’s leukaemia drug Bosulif cut by 13% in Germany after HTA
The retail prices of Pfizer’s leukaemia drug Bosulif (bosutinib) were cut by 13% in Germany on 1 June. This is likely a result of recent price negotiations with GKV-Spitzenverband payer group. Per AMNOG procedure, the negotiations were triggered by Bosulif losing its orphan status in Germany, which was then followed by HTA, in which Bosulif obtained two HTA ratings of no added benefit in two chronic myelogenous leukaemia (CML) indications.
Bosulif’s new retails prices are €779.05 for 28 tablets of a 100mg dose, €2,468.45 for 112 tablets of a 100mg dose and 28 tablets of a 400mg dose and €3,075.94 for 28 tablets of a 500mg dose. The reimbursed price applies for all indications of the drug.
Bosulif is due for reassessment from June 2021 in first-line treatment of CML, following results from an ongoing BFORE study. This will be followed be new pricing negotiations.
By Jack Ziomek – Project Manager